Related Experiment Video
Updated: Aug 21, 2026

Minimally Invasive Endoscopic Intracerebral Hemorrhage Evacuation
Published on: October 15, 2021
Emergent Reversal of Intracranial Hemorrhage Using 4-Factor Prothrombin Complex Concentrate in a Pediatric Patient
Ruchi P Jain1, Keri Bicking, Amanda Clouser
1Department of Pharmacy, Hackensack University Medical Center, Hackensack, NJ.
Background:
Direct oral anticoagulant (DOACs) use for pediatric venous thromboembolism has increased, yet data on reversal strategies using 4-factor prothrombin complex concentrate (4F-PCC) remains limited.
Observation:
We report the first case of intracranial hemorrhage (ICH) in a patient receiving rivaroxaban who underwent reversal with 4F-PCC. An 11-year-old male with sinusitis complicated by multifocal intracranial abscesses, and superior sagittal sinus thrombus treated with rivaroxaban, was found to have ICH. For urgent craniotomy, rivaroxaban was reversed with 2223 units (∼45 units/kg) 4F-PCC. No thromboembolism occurred within 3 months.
Conclusion:
This case adds to the limited literature supporting 4F-PCC for DOAC reversal in pediatrics.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Hemorrhagic Stroke ll: Pathophysiology
Cardiopulmonary Resuscitation IV: Pharmacological Management
Anticoagulant Drugs: Low-Molecular-Weight Heparins
